BioTrends: M&A Malaise

by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 22 years ago

Article

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

over 22 years ago

Article

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

over 22 years ago

Article

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection

over 22 years ago

Article

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

over 22 years ago

Article

The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry

over 22 years ago

Article

Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development

over 22 years ago

Article

Inside Washington: Reshaping Biotech Drug Development

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

BioTrends: M&A Malaise

Articles in this issue

Newsletter

Trending on BioPharm International

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

Implementing Automation and Flexible Design for Allogeneic Manufacturing

Emerging siRNA Platform Offers New Metabolic Disorder Therapies